Corrigendum to "The amino- and carboxyterminal cross-linked telopeptides of collagen type I, NTX-I and CTX-I: A comparative review" [Clinica Chimica Acta 393 (2008) 57-75] (DOI:10.1016/j.cca.2008.03.020);The amino- and carboxyterminal cross-linked telopeptides of collagen type I, NTX-I and CTX-I: A comparative review

Clinica Chimica Acta

Volumn 393, Issue 2, 2008, Pages 57-75

  Herrmann, Markus ^a   Seibel, Markus ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Bone resorption markers; CTX I; NTX I

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; SEX HORMONE;

AGING; BIOCHEMISTRY; BIODEGRADATION; BLOOD LEVEL; BONE TURNOVER; CIRCADIAN RHYTHM; CROSS LINKING; EXERCISE; FRACTURE; HEMODIALYSIS PATIENT; HORMONE BLOOD LEVEL; HUMAN; MENOPAUSE; NUTRITION; OSTEOLYSIS; OSTEOPOROSIS; PATIENT MONITORING; PEPTIDE ANALYSIS; PRIORITY JOURNAL; REVIEW; SEASONAL VARIATION; THERMAL EXPOSURE; URINE LEVEL;

EID: 44449141779     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2008.07.008     Document Type: Erratum

References (237)

1. Lippuner K., Golder M., and Greiner R. Epidemiology and direct medical costs of osteoporotic fractures in men and women in Switzerland. Osteoporos Int 16 (2005) S8-S17
2. Walker-Bone K., Walter G., and Cooper C. Recent developments in the epidemiology of osteoporosis. Curr Opin Rheumatol 14 (2002) 411-415
3. Kanis J.A. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359 (2002) 1929-1936
4. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 843 (1994) 1-129
5. Chavassieux P., Seeman E., and Delmas P.D. Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease. Endocr Rev 28 (2007) 151-164
6. Felsenberg D., and Boonen S. The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Ther 27 (2005) 1-11
7. Oxlund H., Barckman M., Ortoft G., and Andreassen T.T. Reduced concentrations of collagen cross-links are associated with reduced strength of bone. Bone 17 (1995) 365S-371S
8. Oxlund H., Mosekilde L., and Ortoft G. Reduced concentration of collagen reducible cross links in human trabecular bone with respect to age and osteoporosis. Bone 19 (1996) 479-484
9. Banse X., Sims T.J., and Bailey A.J. Mechanical properties of adult vertebral cancellous bone: correlation with collagen intermolecular cross-links. J Bone Miner Res 17 (2002) 1621-1628
10. Banse X., Devogelaer J.P., Lafosse A., Sims T.J., Grynpas M., and Bailey A.J. Cross-link profile of bone collagen correlates with structural organization of trabeculae. Bone 31 (2002) 70-76
11. Seibel M.J. Biochemical markers of bone turnover part II: clinical applications in the management of osteoporosis. Clin Biochem Rev 27 (2006) 123-138
12. Fall P.M., Kennedy D., Smith J.A., Seibel M.J., and Raisz L.G. Comparison of serum and urine assays for biochemical markers of bone resorption in postmenopausal women with and without hormone replacement therapy and in men. Osteoporos Int 11 (2000) 481-485
13. Delmas P.D. Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int 11 (2000) 66-76
14. Hanson D.A., and Eyre D.R. Molecular site specificity of pyridinoline and pyrrole cross-links in type I collagen of human bone. J Biol Chem 271 (1996) 26508-26516
15. Knott L., and Bailey A.J. Collagen cross-links in mineralizing tissues: a review of their chemistry, function, and clinical relevance. Bone 22 (1998) 181-187
16. Knott L., Tarlton J.F., and Bailey A.J. Chemistry of collagen cross-linking: biochemical changes in collagen during the partial mineralization of turkey leg tendon. Biochem J 322 (1997) 535-542
17. Kuypers R., Tyler M., Kurth L.B., Jenkins I.D., and Horgan D.J. Identification of the loci of the collagen-associated Ehrlich chromogen in type I collagen confirms its role as a trivalent cross-link. Biochem J 283 (1992) 129-136
18. Robins S.P. Collagen crosslinks in metabolic bone disease. Acta Orthop Scand 666 (1995) 171-175
19. Allanore Y., Borderie D., Lemarechal H., Cherruau B., Ekindjian O.G., and Kahan A. Correlation of serum collagen I carboxyterminal telopeptide concentrations with cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol 30 (2003) 68-73
20. Scheja A., Wildt M., Wollheim F.A., Akesson A., and Saxne T. Circulating collagen metabolites in systemic sclerosis. Differences between limited and diffuse form and relationship with pulmonary involvement. Rheumatology (Oxford) 39 (2000) 1110-1113
21. Esterre P., Risteli L., and Ricard-Blum S. Immunohistochemical study of type I collagen turn-over and of matrix metalloproteinases in chromoblastomycosis before and after treatment by terbinafine. Pathol Res Pract 194 (1998) 847-853
22. Klappacher G., Franzen P., Haab D., et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol 75 (1995) 913-918
23. Kunishige M., Kijima Y., Sakai T., et al. Transient enhancement of oxidant stress and collagen turnover in patients with acute worsening of congestive heart failure. Circ J 71 (2007) 1893-1897
24. Hanson D.A., Weis M.A., Bollen A.M., Maslan S.L., Singer F.R., and Eyre D.R. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 7 (1992) 1251-1258
25. Apone S., Fevold K., Lee M., and Eyre D.R. A rapid method for quantifying osteoclast activity in vitro. J Bone Miner Res 9 (1998) S178
26. Eyre D.R. The specificity of collagen cross-links as markers of bone and connective tissue degradation. Acta Orthop Scand, Suppl 266 (1995) 166-170
27. Gertz B.J., Shao P., Hanson D.A., et al. Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine. J Bone Miner Res 9 (1994) 135-142
28. Brady J.D., Ju J., and Robins S.P. Isoaspartyl bond formation within N-terminal sequences of collagen type I: implications for their use as markers of collagen degradation. Clin Sci (Lond) 96 (1999) 209-215
29. McCudden C.R., and Kraus V.B. Biochemistry of amino acid racemization and clinical application to musculoskeletal disease. Clin Biochem 39 (2006) 1112-1130
30. Clemens J.D., Herrick M.V., Singer F.R., and Eyre D.R. Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption. Clin Chem 43 (1997) 2058-2063
31. Bekker P.J., Holloway D.L., Rasmussen A.S., et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. 2004. J Bone Miner Res 20 (2005) 2275-2282
32. Ali S.M., Demers L.M., Leitzel K., et al. Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann Oncol 15 (2004) 455-459
33. Guillemant J.A., Accarie C.M., de la Gueronniere V., and Guillemant S.E. Different acute responses of serum type I collagen telopeptides, CTX, NTX and ICTP, after repeated ingestion of calcium. Clin Chim Acta 337 (2003) 35-41
34. Scariano J.K., Garry P.J., Montoya G.D., Duran-Valdez E., and Baumgartner R.N. Diagnostic efficacy of serum cross-linked N-telopeptide (NTx) and aminoterminal procollagen extension propeptide (PINP) measurements for identifying elderly women with decreased bone mineral density. Scand J Clin Lab Invest 62 (2002) 237-243
35. Greenspan S.L., Rosen H.N., and Parker R.A. Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab 85 (2000) 3537-3540
36. Chandani A.K., Scariano J.K., Glew R.H., Clemens J.D., Garry P.J., and Baumgartner R.N. Bone mineral density and serum levels of aminoterminal propeptides and cross-linked N-telopeptides of type I collagen in elderly men. Bone 26 (2000) 513-518
37. Eastell R., Mallinak N., Weiss S., et al. Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women. J Bone Miner Res 15 (2000) 594-598
38. Scariano J.K., Glew R.H., Bou-Serhal C.E., Clemens J.D., Garry P.J., and Baumgartner R.N. Serum levels of cross-linked N-telopeptides and aminoterminal propeptides of type I collagen indicate low bone mineral density in elderly women. Bone 23 (1998) 471-477
39. Garnero P., Borel O., Gineyts E., et al. Extracellular post-translational modifications of collagen are major determinants of biomechanical properties of fetal bovine cortical bone. Bone 38 (2006) 300-309
40. Fledelius C., Johnsen A.H., Cloos P.A., Bonde M., and Qvist P. Characterization of urinary degradation products derived from type I collagen. Identification of a beta-isomerized Asp-Gly sequence within the C-terminal telopeptide (alpha1) region. J Biol Chem 272 (1997) 9755-9763
41. Cloos P.A., and Fledelius C. Collagen fragments in urine derived from bone resorption are highly racemized and isomerized: a biological clock of protein aging with clinical potential. Biochem J 345 (2000) 473-480
42. Cloos P.A., and Christgau S. Non-enzymatic covalent modifications of proteins: mechanisms, physiological consequences and clinical applications. Matrix Biol 21 (2002) 39-52
43. Cloos P.A., Christgau S., Lyubimova N., Body J.J., Qvist P., and Christiansen C. Breast cancer patients with bone metastases are characterised by increased levels of nonisomerised type I collagen fragments. Breast Cancer Res 5 (2003) R103-R109
44. Cloos P.A., Fledelius C., Christgau S., et al. Investigation of bone disease using isomerized and racemized fragments of type I collagen. Calcif Tissue Int 72 (2003) 8-17
45. Cloos P.A., Lyubimova N., Solberg H., et al. An immunoassay for measuring fragments of newly synthesized collagen type I produced during metastatic invasion of bone. Clin Lab 50 (2004) 279-289
46. Bonde M., Garnero P., Fledelius C., Qvist P., Delmas P.D., and Christiansen C. Measurement of bone degradation products in serum using reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen. J Bone Miner Res 12 (1997) 1028-1034
47. Gerdhem P., Ivaska K.K., Alatalo S.L., et al. Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 19 (2004) 386-393
48. Garnero P., Cloos P., Sornay-Rendu E., Qvist P., and Delmas P.D. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study. J Bone Miner Res 17 (2002) 826-833
49. Peichl P., Griesmacherb A., Marteau R., et al. Serum crosslaps in comparison to serum osteocalcin and urinary bone resorption markers. Clin Biochem 34 (2001) 131-139
50. Traba M.L., Calero J.A., Mendez-Davila C., Garcia-Moreno C., and de la P.C. Different behaviors of serum and urinary CrossLaps ELISA in the assessment of bone resorption in healthy girls. Clin Chem 45 (1999) 682-683
51. Kawana K., Takahashi M., Hoshino H., and Kushida K. Comparison of serum and urinary C-terminal telopeptide of type I collagen in aging, menopause and osteoporosis. Clin Chim Acta 316 (2002) 109-115
52. Herrmann M., Pape G., and Herrmann W. Measurement of serum beta-crosslaps is influenced by proteolytic conditions. Clin Chem Lab Med 40 (2002) 790-794
53. Herrmann M., Pape G., and Herrmann W. Stability of serum beta-crosslaps during storage: influence of pH and storage temperature. Clin Chem 47 (2001) 939-940
54. Blumsohn A., Colwell A., Naylor K., and Eastell R. Effect of light and gamma-irradiation on pyridinolines and telopeptides of type I collagen in urine. Clin Chem 41 (1995) 1195-1197
55. Schober E.A., Breusch S.J., and Schneider U. Instability and variability of urinary telopeptides and free crosslinks. Clin Chim Acta 324 (2002) 73-79
56. Mautalen C.A. Circadian rhythm of urinary total and free hydroxyproline excretion and its relation to creatinine excretion. J Lab Clin Med 75 (1970) 11-18
57. Eastell R., Calvo M.S., Burritt M.F., Offord K.P., Russell R.G., and Riggs B.L. Abnormalities in circadian patterns of bone resorption and renal calcium conservation in type I osteoporosis. J Clin Endocrinol Metab 74 (1992) 487-494
58. Li Y., Woitge W., and Kissling C. Biological variability of serum immunoreactive bone sialoprotein. Clin Lab 44 (1998) 553-555
59. Jensen J.E., Kollerup G., Sorensen H.A., and Sorensen O.H. Intraindividual variability in bone markers in the urine. Scand J Clin Lab Invest Suppl 227 (1997) 29-34
60. Sarno M., Powell H., Tjersland G., et al. A collection method and high-sensitivity enzyme immunoassay for sweat pyridinoline and deoxypyridinoline cross-links. Clin Chem 45 (1999) 1501-1509
61. Schlemmer A., and Hassager C. Acute fasting diminishes the circadian rhythm of biochemical markers of bone resorption. Eur J Endocrinol 140 (1999) 332-337
62. Wichers M., Schmidt E., Bidlingmaier F., and Klingmuller D. Diurnal rhythm of CrossLaps in human serum. Clin Chem 45 (1999) 1858-1860
63. Nielsen H.K., Brixen K., Kassem M., Christensen S.E., and Mosekilde L. Diurnal rhythm in serum osteocalcin: relation with sleep, growth hormone, and PTH(1-84). Calcif Tissue Int 49 (1991) 373-377
64. Nielsen H.K., Laurberg P., Brixen K., and Mosekilde L. Relations between diurnal variations in serum osteocalcin, cortisol, parathyroid hormone, and ionized calcium in normal individuals. Acta Endocrinol (Copenh) 124 (1991) 391-398
65. Heymsfield S.B., Arteaga C., McManus C., Smith J., and Moffitt S. Measurement of muscle mass in humans: validity of the 24-hour urinary creatinine method. Am J Clin Nutr 37 (1983) 478-494
66. Bollen A.M., Martin M.D., Leroux B.G., and Eyre D.R. Circadian variation in urinary excretion of bone collagen cross-links. J Bone Miner Res 10 (1995) 1885-1890
67. Holst J.J., Hartmann B., Gottschalck I.B., Jeppesen P.B., Miholic J., and Henriksen D.B. Bone resorption is decreased postprandially by intestinal factors and glucagon-like peptide-2 is a possible candidate. Scand J Gastroenterol 42 (2007) 814-820
68. Henriksen D.B., Alexandersen P., Bjarnason N.H., et al. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res 18 (2003) 2180-2189
69. Bjarnason N.H., Henriksen E.E., Alexandersen P., Christgau S., Henriksen D.B., and Christiansen C. Mechanism of circadian variation in bone resorption. Bone 30 (2002) 307-313
70. Aoe S., Koyama T., Toba Y., Itabashi A., and Takada Y. A controlled trial of the effect of milk basic protein (MBP) supplementation on bone metabolism in healthy menopausal women. Osteoporos Int 16 (2005) 2123-2128
71. Toba Y., Takada Y., Matsuoka Y., et al. Milk basic protein promotes bone formation and suppresses bone resorption in healthy adult men. Biosci Biotechnol Biochem 65 (2001) 1353-1357
72. Yamori Y., Moriguchi E.H., Teramoto T., et al. Soybean isoflavones reduce postmenopausal bone resorption in female Japanese immigrants in Brazil: a ten-week study. J Am Coll Nutr 21 (2002) 560-563
73. Griel A.E., Kris-Etherton P.M., Hilpert K.F., Zhao G., West S.G., and Corwin R.L. An increase in dietary n-3 fatty acids decreases a marker of bone resorption in humans. Nutr J 6 (2007) 2
74. Hampson G., Martin F.C., Moffat K., et al. Effects of dietary improvement on bone metabolism in elderly underweight women with osteoporosis: a randomized controlled trial. Osteoporos Int 14 (2003) 750-756
75. Karp H.J., Vaihia K.P., Karkkainen M.U., Niemisto M.J., and Lamberg-Allardt C.J. Acute effects of different phosphorus sources on calcium and bone metabolism in young women: a whole-foods approach. Calcif Tissue Int 80 (2007) 251-258
76. Jajoo R., Song L., Rasmussen H., Harris S.S., and wson-Hughes B. Dietary acid-base balance, bone resorption, and calcium excretion. J Am Coll Nutr 25 (2006) 224-230
77. Kristensen M., Jensen M., Kudsk J., Henriksen M., and Molgaard C. Short-term effects on bone turnover of replacing milk with cola beverages: a 10-day interventional study in young men. Osteoporos Int 16 (2005) 1803-1808
78. Iwamoto J., Takeda T., Sato Y., and Uzawa M. Effect of whole-body vibration exercise on lumbar bone mineral density, bone turnover, and chronic back pain in postmenopausal osteoporotic women treated with alendronate. Aging Clin Exp Res 17 (2005) 157-163
79. Maimoun L., Manetta J., Couret I., et al. The intensity level of physical exercise and the bone metabolism response. Int J Sports Med 27 (2006) 105-111
80. Maimoun L., Simar D., Malatesta D., et al. Response of bone metabolism related hormones to a single session of strenuous exercise in active elderly subjects. Br J Sports Med 39 (2005) 497-502
81. Herrmann M., Muller M., Scharhag J., Sand-Hill M., Kindermann W., and Herrmann W. The effect of endurance exercise-induced lactacidosis on biochemical markers of bone turnover. Clin Chem Lab Med 45 (2007) 1381-1389
82. Szulc P., Seeman E., and Delmas P.D. Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int 11 (2000) 281-294
83. Fares J.E., Choucair M., Nabulsi M., Salamoun M., Shahine C.H., and Fuleihan G. Effect of gender, puberty, and vitamin D status on biochemical markers of bone remodeling. Bone 33 (2003) 242-247
84. Matsukura T., Kagamimori S., Nishino H., et al. The characteristics of bone turnover in the second decade in relation to age and puberty development in healthy Japanese male and female subjects-Japanese Population-based Osteoporosis Study. Ann Hum Biol 30 (2003) 13-25
85. Eastell R., Delmas P.D., Hodgson S.F., Eriksen E.F., Mann K.G., and Riggs B.L. Bone formation rate in older normal women: concurrent assessment with bone histomorphometry, calcium kinetics, and biochemical markers. J Clin Endocrinol Metab 67 (1988) 741-748
86. Kelly P.J., Pocock N.A., Sambrook P.N., and Eisman J.A. Age and menopause-related changes in indices of bone turnover. J Clin Endocrinol Metab 69 (1989) 1160-1165
87. Beardsworth L.J., Eyre D.R., and Dickson I.R. Changes with age in the urinary excretion of lysyl- and hydroxylysylpyridinoline, two new markers of bone collagen turnover. J Bone Miner Res 5 (1990) 671-676
88. Seibel M.J., Woitge H., Scheidt-Nave C., et al. Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis: results of a pilot study. J Bone Miner Res 9 (1994) 1433-1440
89. Cantatore F.P., Carrozzo M., Magli D., D'Amore M., and Pipitone V. Serum osteocalcin levels in normal humans of different sex and age. An epidemiological study. Panminerva Med 30 (1988) 23-25
90. Catherwood B.D., Marcus R., Madvig P., and Cheung A.K. Determinants of bone gammacarboxyglutamic acid-containing protein in plasma of healthy aging subjects. Bone 6 (1985) 9-13
91. Epstein S., Poser J., McClintock R., Johnston Jr. C.C., Bryce G., and Hui S. Differences in serum bone GLA protein with age and sex. Lancet 1 (1984) 307-310
92. Galli M., and Caniggia M. Osteocalcin in normal adult humans of different sex and age. Horm Metab Res 17 (1985) 165-166
93. Garnero P., and Delmas P.D. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 77 (1993) 1046-1053
94. Hassager C., Risteli J., Risteli L., and Christiansen C. Effect of the menopause and hormone replacement therapy on the carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen. Osteoporos Int 4 (1994) 349-352
95. Midtby M., Magnus J.H., and Joakimsen R.M. The Tromso Study: a population-based study on the variation in bone formation markers with age, gender, anthropometry and season in both men and women. Osteoporos Int 12 (2001) 835-843
96. Sgherzi M.R., Fabbri G., Bonati M., et al. Episodic changes of serum procollagen type I carboxy-terminal propeptide levels in fertile and postmenopausal women. Gynecol Obstet Investig 38 (1994) 60-64
97. Seifert-Klauss V., Mueller J.E., Luppa P., et al. Bone metabolism during the perimenopausal transition: a prospective study. Maturitas 41 (2002) 23-33
98. Garnero P., Sornay-Rendu E., Chapuy M.C., and Delmas P.D. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 11 (1996) 337-349
99. Wishart J.M., Need A.G., Horowitz M., Morris H.A., and Nordin B.E. Effect of age on bone density and bone turnover in men. Clin Endocrinol (Oxf) 42 (1995) 141-146
100. Khosla S., Melton III L.J., Atkinson E.J., O'Fallon W.M., Klee G.G., and Riggs B.L. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 83 (1998) 2266-2274
101. Orwoll E.S., Bell N.H., Nanes M.S., et al. Collagen N-telopeptide excretion in men: the effects of age and intrasubject variability. J Clin Endocrinol Metab 83 (1998) 3930-3935
102. Gallagher J.C., Kinyamu H.K., Fowler S.E., wson-Hughes B., Dalsky G.P., and Sherman S.S. Calciotropic hormones and bone markers in the elderly. J Bone Miner Res 13 (1998) 475-482
103. Tsai K.S., Pan W.H., Hsu S.H., et al. Sexual differences in bone markers and bone mineral density of normal Chinese. Calcif Tissue Int 59 (1996) 454-460
104. Fatayerji D., and Eastell R. Age-related changes in bone turnover in men. J Bone Miner Res 14 (1999) 1203-1210
105. Hannon R., and Eastell R. Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int 11 (2000) S30-S44
106. Bernardi D., Zaninotto M., and Plebani M. Requirements for improving quality in the measurement of bone markers. Clin Chim Acta 346 (2004) 79-86
107. Popp-Snijders C., Lips P., and Netelenbos J.C. Intra-individual variation in bone resorption markers in urine. Ann Clin Biochem 33 (1996) 347-348
108. Gorai I., Chaki O., Nakayama M., and Minaguchi H. Urinary biochemical markers for bone resorption during the menstrual cycle. Calcif Tissue Int 57 (1995) 100-104
109. Scharla S.H., Scheidt-Nave C., Leidig G., et al. Lower serum 25-hydroxyvitamin D is associated with increased bone resorption markers and lower bone density at the proximal femur in normal females: a population-based study. Exp Clin Endocrinol Diabetes 104 (1996) 289-292
110. Morgan D.B., Rivlin R.S., and Davis R.H. Seasonal changes in the urinary excretion of calcium. Am J Clin Nutr 25 (1972) 652-654
111. Bhattoa H.P., Bettembuk P., Ganacharya S., and Balogh A. Prevalence and seasonal variation of hypovitaminosis D and its relationship to bone metabolism in community dwelling postmenopausal Hungarian women. Osteoporos Int 15 (2004) 447-451
112. Munday K., Ginty F., Fulford A., and Bates C.J. Relationships between biochemical bone turnover markers, season, and inflammatory status indices in prepubertal Gambian boys. Calcif Tissue Int 79 (2006) 15-21
113. Woitge H.W., Knothe A., Witte K., et al. Circaannual rhythms and interactions of vitamin D metabolites, parathyroid hormone, and biochemical markers of skeletal homeostasis: a prospective study. J Bone Miner Res 15 (2000) 2443-2450
114. Blumsohn A., Naylor K.E., Timm W., Eagleton A.C., Hannon R.A., and Eastell R. Absence of marked seasonal change in bone turnover: a longitudinal and multicenter crosssectional study. J Bone Miner Res 18 (2003) 1274-1281
115. Woitge H.W., Pecherstorfer M., Li Y., et al. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res 14 (1999) 792-801
116. Chen J.S., Cameron I.D., Cumming R.G., et al. Effect of age-related chronic immobility on markers of bone turnover. J Bone Miner Res 21 (2006) 324-331
117. Zipfel S., Seibel M.J., Lowe B., Beumont P.J., Kasperk C., and Herzog W. Osteoporosis in eating disorders: a follow-up study of patients with anorexia and bulimia nervosa. J Clin Endocrinol Metab 86 (2001) 5227-5233
118. Rauchenzauner M., Schmid A., Heinz-Erian P., et al. Sex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 years. J Clin Endocrinol Metab 92 (2007) 443-449
119. Crofton P.M., Evans N., Taylor M.R., and Holland C.V. Serum CrossLaps: pediatric reference intervals from birth to 19 years of age. Clin Chem 48 (2002) 671-673
120. de Papp A.E., Bone H.G., Caulfield M.P., et al. A cross-sectional study of bone turnover markers in healthy premenopausal women. Bone 40 (2007) 1222-1230
121. Pi Y.Z., Wu X.P., Liu S.P., et al. Age-related changes in bone biochemical markers and their relationship with bone mineral density in normal Chinese women. J Bone Miner Metab 24 (2006) 380-385
122. Szulc P., Garnero P., Munoz F., Marchand F., and Delmas P.D. Cross-sectional evaluation of bone metabolism in men. J Bone Miner Res 16 (2001) 1642-1650
123. Sambrook P.N., Chen C.J., March L., et al. High bone turnover is an independent predictor of mortality in the frail elderly. J Bone Miner Res 21 (2006) 549-555
124. Chen J.S., Seibel M.J., Zochling J., et al. Calcaneal ultrasound but not bone turnover predicts fractures in vitamin D deficient frail elderly at high risk of falls. Calcif Tissue Int 79 (2006) 37-42
125. van der Sluis I., Hop W.C., van Leeuwen J.P., Pols H.A., and de Muinck-Keizer-Schrama S.M. A cross-sectional study on biochemical parameters of bone turnover and vitamin d metabolites in healthy Dutch children and young adults. Horm Res 57 (2002) 170-179
126. Gertz B.J., Clemens J.D., Holland S.D., Yuan W., and Greenspan S. Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int 63 (1998) 102-106
127. Scariano J.K., Garry P.J., Montoya G.D., Wilson J.M., and Baumgartner R.N. Critical differences in the serial measurement of three biochemical markers of bone turnover in the sera of pre- and postmenopausal women. Clin Biochem 34 (2001) 639-644
128. Weiss L.A., Barrett-Connor E., von M.D., and Clark P. Leptin predicts BMD and bone resorption in older women but not older men: the Rancho Bernardo study. J Bone Miner Res 21 (2006) 758-764
129. Valimaki V.V., Alfthan H., Ivaska K.K., et al. Serum estradiol, testosterone, and sex hormone-binding globulin as regulators of peak bone mass and bone turnover rate in young Finnish men. J Clin Endocrinol Metab 89 (2004) 3785-3789
130. Kojima T., Kojima M., Noda K., Ishiguro N., and Poole A.R. Influences of menopause, aging, and gender on the cleavage of type II collagen in cartilage in relationship to bone turnover. Menopause (2007) Electronic publication ahead of print
131. Seifert-Klauss V., Laakmann J., Rattenhuber J., Hoss C., Luppa P., and Kiechle M. [Bone metabolism, bone density and estrogen levels in perimenopause: a prospective 2-year-study]. Zentralbl Gynakol 127 (2005) 132-139
132. Rosenbrock H., Seifert-Klauss V., Kaspar S., Busch R., and Luppa P.B. Changes of biochemical bone markers during the menopausal transition. Clin Chem Lab Med 40 (2002) 143-151
133. Baca E.A., Ulibarri V.A., Scariano J.K., et al. Increased serum levels of N-telopeptides (NTx) of bone collagen in postmenopausal Nigerian women. Calcif Tissue Int 65 (1999) 125-128
134. Meier C., Woitge H.W., Witte K., Lemmer B., and Seibel M.J. Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial. J Bone Miner Res 19 (2004) 1221-1230
135. Cleghorn D.B., O'Loughlin P.D., Schroeder B.J., and Nordin B.E. An open, crossover trial of calcium-fortified milk in prevention of early postmenopausal bone loss. Med J Aust 175 (2001) 242-245
136. Meunier P.J., Jenvrin C., Munoz F., de la Gueronnière V., Garnero P., and Menz M. Consumption of a high calcium mineral water lowers biochemical indices of bone remodeling in postmenopausal women with low calcium intake. Osteoporos Int 16 (2005) 1203-1209
137. Rosen C.J., Chesnut III C.H., and Mallinak N.J. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab 82 (1997) 1904-1910
138. Rosen H.N., Parker R.A., Greenspan S.L., et al. Evaluation of ability of biochemical markers of bone turnover to predict a response to increased doses of HRT. Calcif Tissue Int 74 (2004) 415-423
139. Chesnut III C.H., Bell N.H., Clark G.S., et al. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 102 (1997) 29-37
140. Harris S.T., Eriksen E.F., Davidson M., et al. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 86 (2001) 1890-1897
141. Heikkinen A.M., Parviainen M., Niskanen L., et al. Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study. J Clin Endocrinol Metab 82 (1997) 2476-2482
142. Prestwood K.M., Pilbeam C.C., Burleson J.A., et al. The short-term effects of conjugated estrogen on bone turnover in older women. J Clin Endocrinol Metab 79 (1994) 366-371
143. Greenspan S.L., Resnick N.M., and Parker R.A. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 90 (2005) 2762-2767
144. Kushida K., Takahashi M., Kawana K., and Inoue T. Comparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects, and osteoporosis patients. J Clin Endocrinol Metab 80 (1995) 2447-2450
145. Seibel M.J., Cosman F., Shen V., et al. Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis. J Bone Miner Res 8 (1993) 881-889
146. Charles P., Hasling C., Risteli L., Risteli J., Mosekilde L., and Eriksen E.F. Assessment of bone formation by biochemical markers in metabolic bone disease: separation between osteoblastic activity at the cell and tissue level. Calcif Tissue Int 51 (1992) 406-411
147. Garnero P., Shih W.J., Gineyts E., Karpf D.B., and Delmas P.D. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79 (1994) 1693-1700
148. McLaren A.M., Hordon L.D., Bird H.A., and Robins S.P. Urinary excretion of pyridinium crosslinks of collagen in patients with osteoporosis and the effects of bone fracture. Ann Rheum Dis 51 (1992) 648-651
149. Meier C., Meinhardt U., Greenfield J.R., et al. Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease. Clin Lab 52 (2006) 1-10
150. Schneider D.L., and Barrett-Connor E.L. Urinary N-telopeptide levels discriminate normal, osteopenic, and osteoporotic bone mineral density. Arch Intern Med 157 (1997) 1241-1245
151. Reginster J.Y., Henrotin Y., Christiansen C., et al. Bone resorption in post-menopausal women with normal and low BMD assessed with biochemical markers specific for telopeptide derived degradation products of collagen type I. Calcif Tissue Int 69 (2001) 130-137
152. Pouilles J.M., Tremollieres F.A., and Ribot C. Osteoporosis in otherwise healthy perimenopausal and early postmenopausal women: physical and biochemical characteristics. Osteoporos Int 17 (2006) 193-200
153. Meier C., Nguyen T.V., Center J.R., Seibel M.J., and Eisman J.A. Bone resorption and osteoporotic fractures in elderly men: the dubbo osteoporosis epidemiology study. J Bone Miner Res 20 (2005) 579-587
154. Drake W.M., Kendler D.L., Rosen C.J., and Orwoll E.S. An investigation of the predictors of bone mineral density and response to therapy with alendronate in osteoporotic men. J Clin Endocrinol Metab 88 (2003) 5759-5765
155. Hansen M.A. Assessment of age and risk factors on bone density and bone turnover in healthy premenopausal women. Osteoporos Int 4 (1994) 123-128
156. Dresner-Pollak R., Parker R.A., Poku M., Thompson J., Seibel M.J., and Greenspan S.L. Biochemical markers of bone turnover reflect femoral bone loss in elderly women. Calcif Tissue Int 59 (1996) 328-333
157. Christiansen C., Riis B.J., and Rodbro P. Prediction of rapid bone loss in postmenopausal women. Lancet 1 (1987) 1105-1108
158. Christiansen C., Riis B.J., and Rodbro P. Screening procedure for women at risk of developing postmenopausal osteoporosis. Osteoporos Int 1 (1990) 35-40
159. Cosman F., Nieves J., Wilkinson C., Schnering D., Shen V., and Lindsay R. Bone density change and biochemical indices of skeletal turnover. Calcif Tissue Int 58 (1996) 236-243
160. Mole P.A., Walkinshaw M.H., Robins S.P., and Paterson C.R. Can urinary pyridinium crosslinks and urinary oestrogens predict bone mass and rate of bone loss after the menopause?. Eur J Clin Invest 22 (1992) 767-771
161. Reeve J., Pearson J., Mitchell A., et al. Evolution of spinal bone loss and biochemical markers of bone remodeling after menopause in normal women. Calcif Tissue Int 57 (1995) 105-110
162. Ross P.D., and Knowlton W. Rapid bone loss is associated with increased levels of biochemical markers. J Bone Miner Res 13 (1998) 297-302
163. Iki M., Morita A., Ikeda Y., et al. Biochemical markers of bone turnover predict bone loss in perimenopausal women but not in postmenopausal women-the Japanese Population-based Osteoporosis (JPOS) Cohort Study. Osteoporos Int 17 (2006) 1086-1095
164. Garnero P., Sornay-Rendu E., Duboeuf F., and Delmas P.D. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study. J Bone Miner Res 14 (1999) 1614-1621
165. Okuno S., Inaba M., Kitatani K., Ishimura E., Yamakawa T., and Nishizawa Y. Serum levels of C-terminal telopeptide of type I collagen: a useful new marker of cortical bone loss in hemodialysis patients. Osteoporos Int 16 (2005) 501-509
166. Maeno Y., Inaba M., Okuno S., Yamakawa T., Ishimura E., and Nishizawa Y. Serum concentrations of cross-linked N-telopeptides of type I collagen: new marker for bone resorption in hemodialysis patients. Clin Chem 51 (2005) 2312-2317
167. Garnero P., Sornay-Rendu E., Claustrat B., and Delmas P.D. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 15 (2000) 1526-1536
168. Chapurlat R.D., Garnero P., Breart G., Meunier P.J., and Delmas P.D. Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study. Bone 27 (2000) 283-286
169. Garnero P., Hausherr E., Chapuy M.C., et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 11 (1996) 1531-1538
170. Tromp A.M., Ooms M.E., Popp-Snijders C., Roos J.C., and Lips P. Predictors of fractures in elderly women. Osteoporos Int 11 (2000) 134-140
171. Grados F., Brazier M., Kamel S., et al. Prediction of bone mass density variation by bone remodeling markers in postmenopausal women with vitamin D insufficiency treated with calcium and vitamin D supplementation. J Clin Endocrinol Metab 88 (2003) 5175-5179
172. Bauer D.C., Garnero P., Hochberg M.C., et al. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 21 (2006) 292-299
173. Marcus R., Holloway L., Wells B., et al. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. J Bone Miner Res 14 (1999) 1583-1595
174. Kyd P.A., De V.K., Kerkhoff F., Thomas E., and Fairney A. Clinical usefulness of biochemical resorption markers in osteoporosis. Ann Clin Biochem 36 (1999) 483-491
175. Delmas P.D., Licata A.A., Reginster J.Y., et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone 39 (2006) 237-243
176. Ravn P., Clemmesen B., and Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 24 (1999) 237-244
177. Ravn P., Thompson D.E., Ross P.D., and Christiansen C. Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. Bone 33 (2003) 150-158
178. Okabe R., Inaba M., Nakatsuka K., et al. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline. J Bone Miner Metab 22 (2004) 127-131
179. Chen P., Satterwhite J.H., Licata A.A., et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20 (2005) 962-970
180. Delmas P.D., Hardy P., Garnero P., and Dain M. Monitoring individual response to hormone replacement therapy with bone markers. Bone 26 (2000) 553-560
181. Sornay-Rendu E., Garnero P., Munoz F., Duboeuf F., and Delmas P.D. Effect of withdrawal of hormone replacement therapy on bone mass and bone turnover: the OFELY study. Bone 33 (2003) 159-166
182. Dobnig H., Sipos A., Jiang Y., et al. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 90 (2005) 3970-3977
183. Cummings S.R., Karpf D.B., Harris F., et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112 (2002) 281-289
184. Sarkar S., Mitlak B.H., Wong M., Stock J.L., Black D.M., and Harper K.D. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17 (2002) 1-10
185. Li Z., and Meredith M.P. Exploring the relationship between surrogates and clinical outcomes: analysis of individual patient data vs. meta-regression on group-level summary statistics. J Biopharm Stat 13 (2003) 777-792
186. Riggs B.L., Melton III L.J., and O'Fallon W.M. Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone 18 (1996) 197S-201S
187. Reginster J.Y., Sarkar S., Zegels B., et al. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 34 (2004) 344-351
188. Sarkar S., Reginster J.Y., Crans G.G., ez-Perez A., Pinette K.V., and Delmas P.D. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 19 (2004) 394-401
189. Bjarnason N.H., Sarkar S., Duong T., Mitlak B., Delmas P.D., and Christiansen C. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12 (2001) 922-930
190. Eastell R., Barton I., Hannon R.A., Chines A., Garnero P., and Delmas P.D. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18 (2003) 1051-1056
191. Bauer D.C., Black D.M., Garnero P., et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19 (2004) 1250-1258
192. Delmas P.D., Recker R.R., Chesnut III C.H., et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 15 (2004) 792-798
193. McCombs J.S., Thiebaud P., Laughlin-Miley C., and Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48 (2004) 271-287
194. Marwick C. Hormone combination treats women's bone loss. JAMA 272 (1994) 1487
195. Cano A. Compliance to hormone replacement therapy in menopausal women controlled in a third level academic centre. Maturitas 20 (1994) 91-99
196. Faulkner D.L., Young C., Hutchins D., and McCollam J.S. Patient noncompliance with hormone replacement therapy: a nationwide estimate using a large prescription claims database. Menopause 5 (1998) 226-229
197. Chapurlat R.D., and Cummings S.R. Does follow-up of osteoporotic women treated with antiresorptive therapies improve effectiveness?. Osteoporos Int 13 (2002) 738-744
198. Clowes J.A., Peel N.F., and Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89 (2004) 1117-1123
199. Lekkerkerker F., Kanis J.A., Alsayed N., et al. Adherence to treatment of osteoporosis: a need for study. Osteoporos Int 18 (2007) 1311-1317
200. Andress D.L., Endres D.B., Maloney N.A., Kopp J.B., Coburn J.W., and Sherrard D.J. Comparison of parathyroid hormone assays with bone histomorphometry in renal osteodystrophy. J Clin Endocrinol Metab 63 (1986) 1163-1169
201. Solal M.E., Sebert J.L., Boudailliez B., et al. Comparison of intact, midregion, and carboxy terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients. J Clin Endocrinol Metab 73 (1991) 516-524
202. Alvarez L., Torregrosa J.V., Peris P., et al. Effect of hemodialysis and renal failure on serum biochemical markers of bone turnover. J Bone Miner Metab 22 (2004) 254-259
203. Ueda M., Inaba M., Okuno S., et al. Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low PTH. Life Sci 77 (2005) 1130-1139
204. Franke S., Lehmann G., Abendroth K., Hein G., and Stein G. PICP as bone formation and NTx as bone resorption marker in patients with chronic renal failure. Eur J Med Res 3 (1998) 81-88
205. Papapoulos S.E. Paget's disease of bone: clinical, pathogenetic and therapeutic aspects. Bailliere's Clin Endocrinol Metab 11 (1997) 117-143
206. Shankar S., and Hosking D.J. Biochemical assessment of Paget's disease of bone. J Bone Miner Res 21 (2006) 22-27
207. Reid I.R., Davidson J.S., Wattie D., et al. Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone. Bone 35 (2004) 224-230
208. Peris P., Alvarez L., Vidal S., et al. Biochemical response to bisphosphonate therapy in pagetic patients with skull involvement. Calcif Tissue Int 79 (2006) 22-26
209. Alexandersen P., Peris P., Guanabens N., et al. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone. J Bone Miner Res 20 (2005) 588-595
210. Delmas P.D. Biochemical markers of bone turnover in Paget's disease of bone. J Bone Miner Res 14 Suppl 2 (1999) 66-69
211. Alvarez L., Guanabens N., Peris P., et al. Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease. Bone 29 (2001) 447-452
212. Blair J.M., Zhou H., Seibel M.J., and Dunstan C.R. Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nat Clin Pract Oncol 3 (2006) 41-49
213. Brown J.E., Cook R.J., Major P., et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97 (2005) 59-69
214. Woitge H.W., Pecherstorfer M., Horn E., et al. Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma. Br J Cancer 84 (2001) 344-351
215. Seibel M.J. Clinical use of markers of bone turnover in metastatic bone disease. Nat Clin Pract Oncol 2 (2005) 504-517
216. Voorzanger-Rousselot N., Juillet F., Mareau E., Zimmermann J., Kalebic T., and Garnero P. Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation. Br J Cancer 95 (2006) 506-514
217. Tamada T., Sone T., Tomomitsu T., Jo Y., Tanaka H., and Fukunaga M. Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy. J Bone Miner Metab 19 (2001) 45-51
218. Ebert W., Muley T., Herb K.P., and Schmidt-Gayk H. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. Anticancer Res 24 (2004) 3193-3201
219. Brasso K., Christensen I.J., Johansen J.S., et al. Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate 66 (2006) 503-513
220. Garnero P., Buchs N., Zekri J., Rizzoli R., Coleman R.E., and Delmas P.D. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 82 (2000) 858-864
221. Jung K., Lein M., Stephan C., et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 111 (2004) 783-791
222. Garnero P., Ferreras M., Karsdal M.A., et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 18 (2003) 859-867
223. Leeming D.J., Delling G., Koizumi M., et al. Alpha CTX as a biomarker of skeletal invasion of breast cancer: immunolocalization and the load dependency of urinary excretion. Cancer Epidemiol Biomark Prev 15 (2006) 1392-1395
224. Hernandez J.M., Suquia B., Queizan J.A., et al. Bone remodelation markers are useful in the management of monoclonal gammopathies. Hematol J 5 (2004) 480-488
225. Abildgaard N., Brixen K., Eriksen E.F., Kristensen J.E., Nielsen J.L., and Heickendorff L. Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma. Haematologica 89 (2004) 567-577
226. Wolthers O.D., Heuck C., and Heickendorff L. Diurnal variations in serum and urine markers of type I and type III collagen turnover in children. Clin Chem 47 (2001) 1721-1722
227. Hassager C., Risteli J., Risteli L., Jensen S.B., and Christiansen C. Diurnal variation in serum markers of type I collagen synthesis and degradation in healthy premenopausal women. J Bone Miner Res 7 (1992) 1307-1311
228. Kong Q.Q., Sun T.W., Dou Q.Y., et al. Beta-CTX and ICTP act as indicators of skeletal metastasis status in male patients with non-small cell lung cancer. Int J Biol Markers 22 (2007) 214-220
229. Chen T., Berenson J., Vescio R., et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 42 (2002) 1228-1236
230. Lipton A., Demers L., Curley E., et al. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 34 (1998) 2021-2026
231. Brown J.E., McCloskey E.V., Dewar J.A., et al. The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease. Calcif Tissue Int 81 (2007) 341-351
232. Lein M., Wirth M., Miller K., et al. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression. Eur Urol 52 (2007) 1381-1387
233. Coleman R.E., Major P., Lipton A., et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23 (2005) 4925-4935
234. Johansen J.S., Brasso K., Iversen P., et al. Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival. Clin Cancer Res 13 (2007) 3244-3249
235. Ryan C.W., Huo D., Bylow K., et al. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. BJU Int 100 (2007) 70-75
236. Generali D., Berruti A., Tampellini M., et al. The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load. Bone 40 (2007) 182-188
237. van der Sluis I., Hop W.C., van Leeuwen J.P., Pols H.A., and de Muinck Keizer-Schrama S.M. A cross-sectional study on biochemical parameters of bone turnover and vitamin d metabolites in healthy Dutch children and young adults. Horm Res 57 (2002) 170-179